{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Antifungal", "BLISS", "antimicrobial", "blepharitis", "blepharoconjunctivitis", "liposomal ozonated oil"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "37844600", "DateCompleted": {"Year": "2024", "Month": "07", "Day": "10"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "10"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2023", "Month": "10", "Day": "16"}], "ELocationID": ["10.1177/11206721231207116"], "Journal": {"ISSN": "1724-6016", "JournalIssue": {"Volume": "34", "Issue": "3", "PubDate": {"Year": "2024", "Month": "May"}}, "Title": "European journal of ophthalmology", "ISOAbbreviation": "Eur J Ophthalmol"}, "ArticleTitle": "Liposomal ozonated oil effectiveness in the signs and symptoms of blepharitis in usual clinical practice.", "Pagination": {"StartPage": "678", "EndPage": "682", "MedlinePgn": "678-682"}, "Abstract": {"AbstractText": ["To analyze the efficacy of liposomal ozonated oil (Ozonest\u00ae) treatment, in patients with blepharitis or blepharoconjunctivitis, in improving the signs and symptoms of the pathology.", "Exploratory, open-label, prospective, single-arm, pre-post comparative pilot study in usual clinical practice, in 20 patients with blepharitis/blepharoconjunctivitis, receiving treatment with liposomal ozonated oil, one drop in each eye, 4 times a day, for 28 days. Main purpose was to assess whether there was a clinically improvement in the blepharitis specific BLISS questionnaire score. Changes in the 12-item OSDI, in eyelid signs of blepharitis assessed by the physicians were also evaluated among other tests, and there was also a subjective evaluation of the treatment by patients.", "The BLISS score significantly improved from 16.4 before treatment to 11.8 after treatment (<i>p\u2009</i><\u20090.05). The OSDI score was also significantly improved from 27.5 before treatment to 20.5 after treatment (<i>p\u2009</i><\u20090.05). All tests conducted before and after treatment showed significant improvement (<i>p\u2009</i><\u20090.05), except for NIBUT. The treatment received a score of 7 out of 10 by the patients. There were no adverse events in any patient.", "Liposomal ozonated oil treatment showed good efficacy in improving the signs and symptoms of blepharitis/blepharoconjunctivitis, satisfaction of patients, and good safety and tolerability."]}, "AuthorList": [{"Identifier": ["0000-0002-2010-1701"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Ophthalmology, Hospital Cl\u00ednico San Carlos de Madrid, Madrid, Spain."}, {"Identifier": [], "Affiliation": "Universidad Complutense de Madrid, Instituto de Investigaciones Oftalmol\u00f3gicas Ram\u00f3n Castroviejo, Madrid, Spain."}, {"Identifier": [], "Affiliation": "Ocular Surface and Dry Eye Unit, Cl\u00ednica Rementer\u00eda, Madrid, Spain."}], "LastName": "Ben\u00edtez-Del-Castillo", "ForeName": "Jose Manuel", "Initials": "JM"}], "PublicationTypeList": ["Clinical Study", "Comparative Study", "Journal Article", "Comparative Study"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Eur J Ophthalmol", "NlmUniqueID": "9110772", "ISSNLinking": "1120-6721"}, "ChemicalList": [{"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "0", "NameOfSubstance": "Liposomes"}, {"RegistryNumber": "0", "NameOfSubstance": "Oils"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Infective Agents, Local"}], "MeshHeadingList": [{"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Ozone"}, {"QualifierName": ["therapy"], "DescriptorName": "Blepharitis"}, {"QualifierName": [], "DescriptorName": "Liposomes"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": [], "DescriptorName": "Pilot Projects"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Young Adult"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Aged, 80 and over"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Oils"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Anti-Infective Agents, Local"}], "CoiStatement": "Declaration of conflicting interestsThe author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2024", "Month": "5", "Day": "3", "Hour": "6", "Minute": "44"}, {"Year": "2023", "Month": "10", "Day": "17", "Hour": "0", "Minute": "42"}, {"Year": "2023", "Month": "10", "Day": "16", "Hour": "19", "Minute": "2"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37844600", "10.1177/11206721231207116"]}}], "PubmedBookArticle": []}